Emergent BioSolutions Secures Exclusive Worldwide Rights to Valneva’s Zika Vaccine Technology
- Category: Vaccines
- Published on Thursday, 27 July 2017 09:03
- Hits: 745
GAITHERSBURG, MD, USA I July 26, 2017 I Emergent BioSolutions Inc. (NYSE:EBS) today announced a licensing agreement with Valneva SE for global exclusive rights to Valneva’s Zika vaccine technology, ZIKV. Emergent and Valneva will co-develop ZIKV-VLA1601, a highly purified inactivated vaccine candidate against the Zika virus, from preclinical development through completion of a Phase 1 safety and immunogenicity clinical trial. ZIKV-VLA1601, which has shown to elicit functional antibody responses, is based on Valneva’s established inactivated, whole virus manufacturing platform on which its licensed Japanese Encephalitis vaccine was developed and produced.
“Emergent is focused on providing preparedness solutions to public health threats and emerging infectious diseases,” said Adam Havey, executive vice president business operations of Emergent BioSolutions. “This commitment extends beyond acquiring revenue-generating products and advancing our own products to aligning with partners such as Valneva to develop innovative products that could potentially serve the needs of both government customers and the commercial market.”
Under the terms of the agreement, Emergent will pay Valneva €1 million upfront and will get exclusive rights to use Valneva’s intellectual property and know-how related to Zika product development. The companies are expected to enter into a technology transfer agreement at a later time to enable transfer of Valneva’s technology to Emergent’s Bayview manufacturing facility in Baltimore, Maryland.
The companies plan to initiate the Phase 1 trial in late 2017 or early 2018 and will share all costs until the availability of Phase 1 data, which is anticipated within six months from trial initiation. Emergent will have the option to continue the development arrangement with Valneva for a milestone payment of €5 million, upon availability of Phase 1 data. The agreement also provides Valneva potential additional milestone payments of up to €44 million related to product development, approval, commercialization, and product sales, and future royalties on annual net sales.
Emergent has product candidates in various stages of development that target emerging infectious diseases such as Zika, Ebola, dengue, and influenza, including a Zika hyperimmune therapeutic being developed on the company’s hyperimmune platform.
About Emergent BioSolutions
SOURCE: Emergent BioSolutions